Xue‐Zhong Yu

6.1k total citations · 1 hit paper
152 papers, 4.0k citations indexed

About

Xue‐Zhong Yu is a scholar working on Immunology, Hematology and Molecular Biology. According to data from OpenAlex, Xue‐Zhong Yu has authored 152 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Immunology, 60 papers in Hematology and 35 papers in Molecular Biology. Recurrent topics in Xue‐Zhong Yu's work include Immune Cell Function and Interaction (70 papers), T-cell and B-cell Immunology (57 papers) and Hematopoietic Stem Cell Transplantation (52 papers). Xue‐Zhong Yu is often cited by papers focused on Immune Cell Function and Interaction (70 papers), T-cell and B-cell Immunology (57 papers) and Hematopoietic Stem Cell Transplantation (52 papers). Xue‐Zhong Yu collaborates with scholars based in United States, China and Germany. Xue‐Zhong Yu's co-authors include Claudio Anasetti, Chen Liu, Paul J. Martin, David Bastian, Yongxia Wu, Hung Nguyen, Jessica Heinrichs, Dapeng Wang, Michael H. Albert and Steven Schutt and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Xue‐Zhong Yu

143 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The splanchnic mesenchyme is the tissue of origin for pancreatic fibroblasts during homeostasis and tumorigenesis

2023 152 citations Yongxia Wu, Xue‐Zhong Yu et al. profile →

Peers

Countries citing papers authored by Xue‐Zhong Yu

Since Specialization

Citations

This map shows the geographic impact of Xue‐Zhong Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xue‐Zhong Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xue‐Zhong Yu more than expected).

Fields of papers citing papers by Xue‐Zhong Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xue‐Zhong Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xue‐Zhong Yu. The network helps show where Xue‐Zhong Yu may publish in the future.

Co-authorship network of co-authors of Xue‐Zhong Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Xue‐Zhong Yu. A scholar is included among the top collaborators of Xue‐Zhong Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xue‐Zhong Yu. Xue‐Zhong Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Interactive learning system neural network algorithm optimization 2025 ·Scientific Reports ·(unknown), Xue‐Zhong Yu, (unknown), Jun Peng, Deming Li	0
2	ER stress sensor PERK promotes T cell pathogenicity in GVHD by regulating ER-associated degradation 2025 ·Journal of Clinical Investigation ·Qiao Cheng, Hee-Jin Choi, Yongxia Wu, Xiaohong Yuan, (unknown), Linlu Tian, (unknown), (unknown), Reza Alimohammadi, Chen Liu, Xue‐Zhong Yu	0
3	Ceramide-Induced Metabolic Stress Depletes Fumarate and Drives Mitophagy to Mediate Tumor Suppression 2025 ·Cancer Research ·Natalia V. Oleinik, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Zdzisław M. Szulc, Elizabeth G. Hill, Alexander V. Alekseyenko, Hüseyin Çimen, (unknown), Christina Voelkel‐Johnson, Michelle M. Lilly, John J. Lemasters, Norma Frizzell, Xue‐Zhong Yu, Shikhar Mehrotra, Besim Öğretmen	1
4	Early Safety and Feasibility Results from a Phase II Trial of De-Escalated Ptcy and Ruxolitinib for Gvhd Prophylaxis in Older Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT 2024 ·Blood ·Sameem Abedin, Fateeha Furqan, Lyndsey Runaas, Walter Longo, (unknown), Timothy S. Fenske, Marcelo C. Pasquini, William R. Drobyski, Xue‐Zhong Yu, Mehdi Hamadani	0
5	The Astragalus Membranaceus Herb Attenuates Leukemia by Inhibiting the FLI1 Oncogene and Enhancing Anti-Tumor Immunity 2024 ·International Journal of Molecular Sciences ·(unknown), Yaoliang Tang, Chunlin Wang, Wuling Liu, (unknown), Anling Hu, (unknown), Eldad Zacksenhaus, Xue‐Zhong Yu, Xiao Xiao, Yaacov Ben‐David	0
6	Targeting protein tyrosine phosphatases for CDK6-induced immunotherapy resistance 2023 ·Cell Reports ·Xueliang Gao, Yongxia Wu, Joel M. Chick, Andrea M. Abbott, Baishan Jiang, Jingxin Wang, Susana Comte‐Walters, Roger H. Johnson, (unknown), Michael I. Nishimura, Steven P. Gygi, Anand S. Mehta, Denis C. Guttridge, Lauren E. Ball, (unknown), Piotr Siciński, Xue‐Zhong Yu, (unknown)	6
7	Targeting the Complement Alternative Pathway Permits Graft Versus Leukemia Activity while Preventing Graft Versus Host Disease 2020 ·Clinical Cancer Research ·Hung Nguyen, Ali Alawieh, David Bastian, (unknown), Min Dai, Anusara Daenthanasanmak, Mengmeng Zhang, Supinya Iamsawat, Steven Schutt, Yongxia Wu, (unknown), (unknown), Carl Atkinson, Shaoli Sun, Juan Carlos Varela, Stephen Tomlinson, Xue‐Zhong Yu	9
8	RNA binding protein PCBP1 is an intracellular immune checkpoint for shaping T cell responses in cancer immunity 2020 ·Science Advances ·Ephraim Ansa-Addo, (unknown), Brian Riesenberg, Supinya Iamsawat, Davis Borucki, Michelle H. Nelson, Jin Hyun Nam, Dongjun Chung, Chrystal M. Paulos, Bei Liu, Xue‐Zhong Yu, Caroline C. Philpott, Philip H. Howe, Zihai Li	35
9	Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response 2018 ·Clinical Cancer Research ·Shilpak Chatterjee, Paramita Chakraborty, Anusara Daenthanasanmak, Supinya Iamsawat, Gabriela Andrejeva, (unknown), Melissa M. Wolf, (unknown), Carsten Krieg, Craig C. Beeson, Meenal Mehrotra, Elizabeth G. Hill, Jeffery C. Rathmell, Xue‐Zhong Yu, Andrew S. Kraft, Shikhar Mehrotra	43
10	Complement Promotes Gvhd through Suppressing Autophagy in Recipient Dendritic Cells after Allogeneic Hematopoietic Cell Transplantation in Mice 2017 ·Blood ·Hung Nguyen, David Bastian, (unknown), (unknown), David P. Fairlie, Carl Atkinson, Besim Öğretmen, Stephen Tomlinson, Xue‐Zhong Yu	1
11	Oxidative Stress Regulates T Cell Pathogenicity in Gvhd 2017 ·Blood ·M. Hanief Sofi, Yongxia Wu, Min Dai, Steven Schutt, Anusara Daenthanasanmak, Jessica Heinrichs, Hung Nguyen, David Bastian, Supinya Iamsawat, Mengmeng Zhang, Shikhar Mehrotra, Xue‐Zhong Yu	1
12	Reducing CD73 Expression by IL1β-Programmed Th17 Cells Improves Immunotherapeutic Control of Tumors 2014 ·Cancer Research ·Shilpak Chatterjee, (unknown), Pravin Kesarwani, Jin H. Song, (unknown), Jianing Fu, Stefanie R. Bailey, (unknown), Andrew S. Kraft, Chrystal M. Paulos, Xue‐Zhong Yu, Shikhar Mehrotra	46
13	Plasmin Plays an Essential Role in Amplification of Psoriasiform Skin Inflammation in Mice 2011 ·PLoS ONE ·Qun Li, Ke Fang, Weiwei Zhang, Xiaoyan Shen, (unknown), Hong Wang, Xue‐Zhong Yu, Qibin Leng, Honglin Wang	29
14	Abundant c-Fas–associated death domain–like interleukin-1–converting enzyme inhibitory protein expression determines resistance of T helper 17 cells to activation-induced cell death 2009 ·Blood ·Yu Yu, Cristina Iclozan, Tomohide Yamazaki, Xuexian O. Yang, Claudio Anasetti, Chen Dong, Xue‐Zhong Yu	32
15	Alloantigen Affinity and CD4 Help Determine Severity of Graft-versus-Host Disease Mediated by CD8 Donor T Cells 2006 ·The Journal of Immunology ·Xue‐Zhong Yu, Michael H. Albert, Claudio Anasetti	22
16	CD28 ligation induces transplantation tolerance by IFN-γ–dependent depletion of T cells that recognize alloantigens 2004 ·Journal of Clinical Investigation ·Xue‐Zhong Yu, Michael H. Albert, Paul J. Martin, Claudio Anasetti	53
17	Lck Is Required for Activation-Induced T Cell Death after TCR Ligation with Partial Agonists 2004 ·The Journal of Immunology ·Xue‐Zhong Yu, Steven D. Levin, Joaquı́n Madrenas, Claudio Anasetti	15
18	CD28 Signal Enhances Apoptosis of CD8 T Cells After Strong TCR Ligation 2003 ·The Journal of Immunology ·Xue‐Zhong Yu, Paul J. Martin, Claudio Anasetti	30
19	Anti-CD3ε F(ab′)2 Prevents Graft-Versus-Host Disease by Selectively Depleting Donor T Cells Activated by Recipient Alloantigens 2001 ·The Journal of Immunology ·Xue‐Zhong Yu, (unknown), Paul J. Martin, Claudio Anasetti	29
20	Non-Fc Receptor-Binding Humanized Anti-CD3 Antibodies Induce Apoptosis of Activated Human T Cells 2000 ·The Journal of Immunology ·Paul A. Carpenter, (unknown), J. Yun Tso, Oliver W. Press, Theodore A. Gooley, Xue‐Zhong Yu, Claudio Anasetti	74

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact